Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGOS: BMS-986489 FDC vs atezolizumab with carboplatin plus etoposide in first-line ES-SCLC
jRCT2011240075Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of bms-986012 + nivolumab, Atigotatug, nivolumab, atezolizumab, carboplatin and 1 more in small cell lung cancer (SCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall Survival. Started Mar 2025; status: active, not recruiting.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2011240075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240075.